Organisation paid for research Program year 2025 Source: CMS Open Payments

BVL Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$435,408

63 payments

Through program year 2025, BVL Clinical Research is reported as receiving $435,408 in research payments, across 63 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $207,925 24
2024 Research $126,439 22
2023 Research $29,047 6
2022 Research $29,083 6
2021 Research $36,999 2
2020 Research $5,916 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. Teva Pharmaceuticals USA, Inc. $232,218 23 payments
  2. Eli Lilly and Company $66,331 7 payments
  3. Boehringer Ingelheim International GmbH $55,766 5 payments
  4. Amgen Inc. $30,683 5 payments
  5. Genzyme Corporation $17,000 3 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $15,151 10 payments
  7. AstraZeneca UK Limited $6,000 1 payment
  8. Allergan Inc. $5,916 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $5,900 3 payments
  10. AstraZeneca Pharmaceuticals LP $444 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) $139,133 7 payments
  2. A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) $93,084 16 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $55,645 5 payments
  4. Proof of Clinical Principal in Crohn's Disease $49,919 4 payments
  5. Proof of Clinical Principal in Crohn???s Disease $20,999 11 payments
  6. A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis $17,000 3 payments
  7. A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis $15,641 1 payment
  8. P2 UC $15,042 4 payments
  9. A Phase 3 Multicenter Randomized Double-Blind Placebo- and Active- Controlled Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $10,524 1 payment
  10. A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease AMALTHEA $6,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record